Birmingham Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.71M Sell
112,751
-295
-0.3% -$7.72K 1.03% 29
2026
Q1
$3.17M Hold
113,046
1.34% 23
2025
Q4
$2.81M Sell
113,046
-6,800
-6% -$171K 1.24% 26
2025
Q3
$3.05M Sell
119,846
-12,403
-9% -$306K 1.4% 24
2025
Q2
$3.21M Sell
132,249
-30,994
-19% -$723K 1.42% 25
2025
Q1
$4.14M Sell
163,243
-10,344
-6% -$271K 1.56% 24
2024
Q4
$4.61M Sell
173,587
-13,063
-7% -$354K 1.71% 23
2024
Q3
$5.4M Buy
186,650
+4,887
+3% +$143K 1.96% 20
2024
Q2
$5.09M Buy
181,763
+1,559
+0.9% +$42.9K 1.99% 19
2024
Q1
$5M Buy
180,204
+40,209
+29% +$1.12M 1.84% 20
2023
Q4
$4.03M Sell
139,995
-2,363
-2% -$71.4K 1.59% 23
2023
Q3
$4.72M Buy
142,358
+11,888
+9% +$420K 1.95% 17
2023
Q2
$4.79M Sell
130,470
-11,214
-8% -$436K 2% 16
2023
Q1
$5.78M Sell
141,684
-3,535
-2% -$153K 2.31% 12
2022
Q4
$7.44M Sell
145,219
-989
-0.7% -$47.4K 2.82% 11
2022
Q3
$6.4M Sell
146,208
-6,738
-4% -$327K 2.84% 9
2022
Q2
$8.02M Sell
152,946
-380
-0.2% -$19.4K 3.2% 8
2022
Q1
$7.94M Sell
153,326
-3,015
-2% -$156K 2.77% 8
2021
Q4
$9.23M Sell
156,341
-1,125
-0.7% -$55.7K 3.34% 5
2021
Q3
$6.77M Sell
157,466
-2,177
-1% -$96.4K 2.6% 10
2021
Q2
$6.25M Buy
159,643
+2,090
+1% +$81.3K 2.29% 12
2021
Q1
$5.71M Buy
157,553
+1,740
+1% +$61.8K 2.13% 13
2020
Q4
$5.74M Sell
155,813
-8,435
-5% -$309K 2.37% 12
2020
Q3
$5.72M Sell
164,248
-242
-0.1% -$8.48K 2.6% 10
2020
Q2
$5.1M Buy
164,490
+4,147
+3% +$141K 2.49% 12
2020
Q1
$4.96M Sell
160,343
-6,909
-4% -$235K 2.74% 11
2019
Q4
$6.22M Sell
167,252
-2,168
-1% -$77.2K 2.76% 11
2019
Q3
$5.78M Sell
169,420
-2,601
-2% -$94.6K 2.66% 12
2019
Q2
$7.07M Sell
172,021
-3,422
-2% -$136K 3.19% 8
2019
Q1
$7.07M Sell
175,443
-2,924
-2% -$117K 3.17% 8
2018
Q4
$7.39M Sell
178,367
-1,107
-0.6% -$46K 3.6% 5
2018
Q3
$7.5M Sell
179,474
-2,472
-1% -$95.2K 3.1% 7
2018
Q2
$6.26M Sell
181,946
-2,736
-1% -$93.5K 2.69% 11
2018
Q1
$6.22M Sell
184,682
-3,109
-2% -$107K 2.58% 11
2017
Q4
$6.45M Sell
187,791
-2,150
-1% -$73.3K 2.47% 13
2017
Q3
$6.43M Sell
189,941
-3,113
-2% -$100K 2.56% 14
2017
Q2
$6.15M Sell
193,054
-163
-0.1% -$5.14K 2.48% 13
2017
Q1
$6.27M Buy
193,217
+3,511
+2% +$111K 2.54% 13
2016
Q4
$5.85M Buy
189,706
+4,065
+2% +$124K 2.46% 12
2016
Q3
$6.2M Sell
185,641
-1,184
-0.6% -$39.6K 2.74% 8
2016
Q2
$6.24M Sell
186,825
-23,622
-11% -$754K 2.74% 8
2016
Q1
$5.92M Buy
210,447
+1,907
+0.9% +$54.5K 2.41% 16
2015
Q4
$6.39M Buy
208,540
+1,156
+0.6% +$36.4K 2.6% 8
2015
Q3
$6.18M Sell
207,384
-408
-0.2% -$13.1K 2.7% 5
2015
Q2
$6.61M Sell
207,792
-1,250
-0.6% -$40.7K 2.58% 7
2015
Q1
$6.9M Buy
209,042
+8,503
+4% +$270K 2.62% 8
2014
Q4
$5.93M Sell
200,539
-11,318
-5% -$325K 2.28% 14
2014
Q3
$5.94M Buy
211,857
+759
+0.4% +$21.3K 2.25% 17
2014
Q2
$5.94M Buy
211,098
+1,612
+0.8% +$46K 2.17% 18
2014
Q1
$6.38M Sell
209,486
-1,986
-0.9% -$59.2K 2.42% 10
2013
Q4
$6.15M Sell
211,472
-10,367
-5% -$302K 2.32% 10
2013
Q3
$6.05M Buy
221,839
+10,330
+5% +$281K 2.4% 11
2013
Q2
$5.62M Buy
+211,509
New +$5.84M 2.33% 9

Other funds holding PFE

Birmingham Capital Management's PFE Position: Q2 2026 in Review

Birmingham Capital Management reduced its Pfizer (PFE) stake by 0.26% in Q2 2026, selling an estimated $7.72K and leaving 112,751 shares worth $2.71M. The position accounts for 1.03% of the portfolio, ranked #29.

Birmingham Capital Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.23M in Q4 2021. 2,817 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Birmingham Capital Management held 112,751 shares of Pfizer worth $2.71M as of Q2 2026.
  • Birmingham Capital Management sold 295 Pfizer shares in Q2 2026, an estimated $7.72K.
  • Pfizer made up 1.03% of Birmingham Capital Management's portfolio in Q2 2026, its #29 holding.
  • Birmingham Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Birmingham Capital Management's Pfizer position peaked at $9.23M in Q4 2021.
  • 2,817 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Birmingham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.